Cogent Biosciences
COGT
26.72
-1.03
-3.70%
Cogent Biosciences
US · COGT
#2052 by market cap
Listed 2016
26.72
-1.03
-3.70%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:53
About Cogent Biosciences
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
- Founded
- 2014
- CEO
- Mr. Andrews R. Robbins, M.B.A.
- Employees
- 258
- Headquarters
- Waltham, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- cogentbio.com
Company profile
- Exchange
- US
- Symbol
- COGT
- Market-cap rank
- #2052
- Listing date
- 2016-09-26
- Market cap
- 4.65B
- Float cap
- 4.62B
- Shares out
- 173.99M
- Float shares
- 172.99M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 19:53:23 · For reference only, not investment advice and not tailored to your situation.
Cogent Biosciences discussion 0 comments